Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunobridging Study: Immunogenicity and Safety of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia

NCT06259578 is registered in ClinicalTrials.gov with Dr. Soetomo General Hospital as lead sponsor.

NCT NCT06259578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06259578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunobridging Study: Immunogenicity and Safety of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia
Lead sponsor
Dr. Soetomo General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
January 29, 2024
Completion date
December 29, 2024
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic, covid-19 vaccines, covid-19 virus disease